Tumour biology: herceptin acts as an anti-angiogenic cocktail

Nature
Yotaro IzumiRakesh K Jain

Abstract

Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.

References

Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H AllgayerM M Heiss
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R S KerbelJ Rak
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Apr 18, 2001·The Journal of Clinical Investigation·P Bornstein
Jul 19, 2001·Journal of the National Cancer Institute·I J Fidler
Jan 5, 2002·Scientific American·R K Jain, P F Carmeliet
May 11, 2002·Nature Reviews. Cancer·Rakesh K JainDai Fukumura

❮ Previous
Next ❯

Citations

Oct 23, 2008·Cancer Immunology, Immunotherapy : CII·Panagiotis KaragiannisSophia N Karagiannis
Nov 8, 2005·Cancer Chemotherapy and Pharmacology·Masakazu ToiLouis W C Chow
Feb 8, 2008·Cancer Chemotherapy and Pharmacology·Rupert BartschGuenther G Steger
Mar 28, 2008·Cancer Chemotherapy and Pharmacology·Matthew E HardeeMark W Dewhirst
Sep 1, 2005·Investigational New Drugs·Christina H Yeon, Mark D Pegram
Jun 3, 2011·Investigational New Drugs·Hiroyasu KanedaKazuhiko Nakagawa
Mar 5, 2009·Journal of Mammary Gland Biology and Neoplasia·Philippe L BedardMartine J Piccart-Gebhart
Jul 31, 2007·Current Treatment Options in Oncology·Amy Lin, Hope S Rugo
Dec 25, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·L MansoH Cortés-Funes
Apr 20, 2004·Critical Reviews in Oncology/hematology·Amar BennasrounePierre Hubert
Apr 10, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Bradly G WoutersCostas Koumenis
May 28, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Patricia FormentoGérard Milano
Mar 17, 2004·Seminars in Cancer Biology·Janusz Rak, Joanne L Yu
Aug 30, 2003·American Journal of Surgery·Julian A Kim
Mar 22, 2003·Experimental Cell Research·Thomas HolbroNancy E Hynes
May 6, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Moulay A Alaoui-Jamali, He Qiang
Mar 5, 2003·Trends in Molecular Medicine·Marya F McCartyLee M Ellis
Sep 24, 2005·Nature·Sara M Weis, David A Cheresh
Jan 7, 2003·Nature Medicine·Peter J Hudson, Christelle Souriau
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Sep 15, 2010·Nature Reviews. Clinical Oncology·Rakesh K Jain, Triantafyllos Stylianopoulos
Apr 14, 2011·Nature Reviews. Clinical Oncology·April F EichlerRakesh K Jain
Jan 1, 2009·Nature Reviews. Drug Discovery·Véronique Baud, Michael Karin
May 29, 2007·Oncogene·R Nahta, F J Esteva
May 30, 2008·The New England Journal of Medicine·M Dror MichaelsonEsther Oliva
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Mar 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·Pak Kin WongChih-Ming Ho
May 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Shom GoelRakesh K Jain
Oct 17, 2012·Proceedings of the National Academy of Sciences of the United States of America·David P KodackRakesh K Jain
May 5, 2005·DNA and Cell Biology·Mark Richter, Hongtao Zhang
Apr 20, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Marilita M MoschosEmmanouil Agapitos
Mar 7, 2012·Cold Spring Harbor Perspectives in Medicine·Shom GoelRakesh K Jain
Jul 16, 2003·Cold Spring Harbor Symposia on Quantitative Biology·R K Jain
Jul 19, 2012·Biochemistry. Biokhimii︠a︡·O L PolanovskiS M Deyev
Jan 18, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Radwan N SafaDouglas B Sawyer
Jul 12, 2011·Physiological Reviews·Shom GoelRakesh K Jain
Jun 1, 2012·International Journal of Breast Cancer·Andrea L A Wong, Soo-Chin Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.